Advanced

Oral therapy for riboflavin transporter deficiency - What is the regimen of choice?

Gorcenco, Sorina LU ; Vaz, Frédéric M.; Tracewska-Siemiatkowska, Anna; Tranebjærg, Lisbeth; Cremers, Frans P.M.; Ygland, Emil LU ; Kicsi, Jenő; Rendtorff, Nanna Dahl; Möller, Claes and Kjellström, Ulrika LU , et al. (2019) In Parkinsonism & Related Disorders 61. p.245-247
Please use this url to cite or link to this publication:
@article{52ba4849-9c48-42f9-98e4-d655b2fdd48c,
  author       = {Gorcenco, Sorina and Vaz, Frédéric M. and Tracewska-Siemiatkowska, Anna and Tranebjærg, Lisbeth and Cremers, Frans P.M. and Ygland, Emil and Kicsi, Jenő and Rendtorff, Nanna Dahl and Möller, Claes and Kjellström, Ulrika and Andréasson, Sten and Puschmann, Andreas},
  issn         = {1873-5126},
  keyword      = {Adult,Ataxia,Brown-Vialetto-Van Laere syndrome-2,BVVLS2,Pharmacokinetics,Recessive,Riboflavin transporter deficiency,SLC52A2,Treatment},
  language     = {eng},
  pages        = {245--247},
  publisher    = {Elsevier},
  series       = {Parkinsonism & Related Disorders},
  title        = {Oral therapy for riboflavin transporter deficiency - What is the regimen of choice?},
  url          = {http://dx.doi.org/10.1016/j.parkreldis.2018.10.017},
  volume       = {61},
  year         = {2019},
}